MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Advaita Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

iPathwayGuide Now Available in Illumina’s BaseSpace Apps - Advaita Bioinformatics today announced the addition of its iPathwayGuide application to BaseSpace Apps, Illumina’s applications store and informatics community dedicated to advancing genomic analysis - AdvaitaCorporation.com
iPathwayGuide Now Available in Illumina’s BaseSpace Apps

 

NewswireToday - /newswire/ - Plymouth, MI, United States, 2014/06/23 - Advaita Bioinformatics today announced the addition of its iPathwayGuide application to BaseSpace Apps, Illumina’s applications store and informatics community dedicated to advancing genomic analysis - AdvaitaCorporation.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

iPathwayGuide is a web based pathway analysis tool that goes beyond the typical statistical over-representation analysis by taking into account the pathway topology from a systems biology perspective. Advaita has demonstrated that this approach can significantly reduce the number of false positive and false negative results produced by most competing tools. iPathwayGuide also highlights coherent chains of perturbation propagation and drug targets directly on the pathway, so users can quickly focus on potential points of interest. The application provides quick access to a wide array of analyses including: gene analysis, gene-ontology analysis, pathway analysis, drug pathway mapping and disease associations. iPathwayGuide is the only gene-expression analysis tool that goes beyond simple associations and provides a deeper, richer, more comprehensive pathway level analysis.

“We are very excited to offer our iPathwayGuide application to the growing users of Illumina’s BaseSpace,” said Andrew Olson, VP of Business Development at Advaita. “The integration of our tool in BaseSpace will allow the users to seamlessly pipeline their gene expression data and perform a variety of analyses. iPathwayGuide is the most comprehensive systems biology tool available that considers the role and function of each gene to produce to produce biologically meaningful results.”

About Advaita

Advaita Bioinformatics (advaitabio.com), founded in 2005, is focusing on the mission to bridge the gap between the ability to collect biological data and the ability to interpret it through the use of advanced computational methods. Advaita's vision is to leverage advanced computational methods to dramatically reduce drug-development costs, make personalized medicine a clinical reality and shift the emphasis from treating disease to pre-symptomatic detection. Advaita’s analytical tools have helped researchers from premier organizations to translate gigabytes of experimental data into meaningful knowledge. iPathwayGuide is the first web application capable of identifying mechanisms of action and potential drug targets directly from gene-expression experiments. This unique ability can empower users to quickly identify potential drug targets and drug candidates, avoiding costly dead ends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Advaita Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


iPathwayGuide Now Available in Illumina’s BaseSpace Apps

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Arjun Gupta - AdvaitaCorporation.com 
734-922-0110 info[.]advaitacorporation.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Advaita Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Advaita Corporation / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)